Wall Street Zen Downgrades Teleflex (NYSE:TFX) to Sell

Teleflex (NYSE:TFX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also weighed in on TFX. Zacks Research raised shares of Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a report on Friday, March 27th. Mizuho set a $140.00 target price on shares of Teleflex in a report on Friday. Bank of America raised shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target on the stock in a report on Monday, April 13th. Finally, Needham & Company LLC lifted their price target on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $142.86.

Teleflex Price Performance

Shares of TFX opened at $133.17 on Friday. The firm has a market cap of $5.89 billion, a PE ratio of -5.84, a P/E/G ratio of 0.96 and a beta of 0.82. The company has a current ratio of 2.55, a quick ratio of 2.03 and a debt-to-equity ratio of 0.82. The firm has a fifty day simple moving average of $119.44 and a two-hundred day simple moving average of $116.73. Teleflex has a 1-year low of $100.18 and a 1-year high of $139.67.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The business had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities analysts anticipate that Teleflex will post 6.75 EPS for the current year.

Institutional Trading of Teleflex

Several hedge funds have recently made changes to their positions in TFX. AQR Capital Management LLC raised its position in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after buying an additional 1,956,811 shares in the last quarter. Abrams Bison Investments LLC purchased a new stake in shares of Teleflex during the 3rd quarter valued at about $112,317,000. Norges Bank purchased a new stake in shares of Teleflex during the 4th quarter valued at about $66,076,000. Thrivent Financial for Lutherans raised its position in shares of Teleflex by 1,161.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 550,449 shares of the medical technology company’s stock valued at $67,353,000 after buying an additional 506,796 shares in the last quarter. Finally, Wolf Hill Capital Management LP purchased a new stake in shares of Teleflex during the 4th quarter valued at about $47,405,000. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.